The ARCHITECT HAVAb-IgM assay determines the presence of IgM anti-HAV in human serum and plasma. Hepatitis A is a self-limiting disease and is often a subclinical disorder, particularly in children. Since symptomatic hepatitis A virus (HAV) infections can be clinically indistinguishable from infection with hepatitis B or C virus, serological testing is an important tool to achieve proper diagnosis. During the acute phase of HAV infection, IgM anti-HAV appears in the patient’s serum and is nearly always detectable at the onset of symptoms. In most cases, IgM anti-HAV response usually peaks within the first month of illness and can persist for up to six months.
Manufacturer’s Reagent package insert, Architect HAVAb-IgM, October 2016, Abbott Laboratories, MAX-Planck-Ring 65205 Wiesbaden, Germany.